Calmodulin in osteogenic sarcoma

The content of calmodulin in homogenates prepared from various morphological variants of primary osteogenic sarcoma varies from 408 to 14,255 ng/mg total protein and is lowered by neoadjunctive chemotherapy. The 5-year incidence of metastases is lower when the calmodulin content in the tumor is >6000 ng/mg protein. At calmodulin content <6000 ng/mg protein, the occurrence of metastases is lower in patients receiving neoadjunctive therapy before surgery than in untreated patients.